Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 10/20 | 0.55 |
| ▸ | RXRA | P19793 | 2/20 | 0.51 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13349654 | 0.91 | HMGCR (0.57) | HMGCRRXRANR1I2NR4A2PDE4D | |
| SCHEMBL10049194 | 0.87 | HMGCR (0.60) | HMGCRRXRANR1I2NR4A2PDE4D | |
| SCHEMBL13980281 | 0.85 | HMGCR (0.57) | HMGCRRXRANR1I2NR4A2PDE4D | |
| SCHEMBL247234 | 0.85 | HMGCR (0.74) | HMGCRRXRA | |
| SCHEMBL247233 | 0.85 | HMGCR (0.74) | HMGCRRXRA | |
| SCHEMBL7481310 | 0.85 | HMGCR (0.74) | HMGCRRXRA | |
| SCHEMBL7481306 | 0.85 | HMGCR (0.74) | HMGCRRXRA | |
| SCHEMBL9301248 | 0.85 | HMGCR (0.74) | HMGCRRXRA | |
| SCHEMBL14669780 | 0.83 | HMGCR (0.54) | HMGCRRXRANR1I2NR4A2PDE4D | |
| SCHEMBL7899135 | 0.80 | RXRA (0.58) | HMGCRRXRANR1I2NR4A2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732413-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2010-06-08 | — | — | US | disclosed |
| US-20080200446-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
| US-7378518-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2008-05-27 | — | — | US | disclosed |
| US-20070155676-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-07-05 | — | — | US | disclosed |
| US-7208486-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200446-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | CYP46A1, NPC1L1, PCSK9 | HMGCR 18/4885RXRA 2353/4885NR1I2 272/4885 |
| US-20070155676-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | APOB, NPC1L1, CYP46A1 | HMGCR 29/4885RXRA 2593/4885NR1I2 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.